Gland Pharma bags USFDA nod for breast cancer treatment injection Eribulin Mesylate
Hyderabad: Gland Pharma Limited, a generic injectable-focused
pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product).
Eribulin Mesylate Injection is used for the treatment of breast cancer that has spread to other parts of the body.
“The Product is expected to be the first generic approval on the market, and the Company expects to launch
this product in the near term through its marketing partner,” Gland Pharma stated.
The Product has US sales of approximately USD 92 million for twelve months ending in February 2024,
according to IQVIA.
The Company is co-developing several complex injectables, including this Product, with Orbicular
Pharmaceutical Technologies Private Limited.
Read also: Gland Pharma bags tentative USFDA nod for Angiotensin II Injection for low BP treatment
manufacturer of small-volume liquid parenteral products to become injectable-focused
companies, with a global footprint across 60 countries, including the United States, Europe, Canada,
Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model. It has a
wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders,
infusions, oncology, and ophthalmic solutions.
